Table 1

Medical and ocular data in patients with immune recovery vitritis treated with orbital floor steroids

Variable	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Age	35	43	43	46	45	58	37
Sex	M	M	M	M	M	M	M
Date of diagnosis HIV	Jul 94	Jan 94	Feb 96	Jan 90	Jun 90	Jan 96	Sep 97
CMV retinitis:
onset	Apr 96	Feb 96	Jul 96	Feb 95	Jun 95	Mar 96	Dec 97
laterality	BE	BE	LE	BE	BE	BE	BE
location (zone)	RE 3, LE 1 and 3	RE 2 and 3, LE 3	LE 1, 2, and 3	RE 1, 2, and 3, LE 2 and 3	RE 2 and 3, LE 2 and 3	RE 1, 2, and 3, LE 1, 2, and 3	RE 1, 2, and 3, LE 1, 2, and 3
treatment	IV foscarnet +	IV foscarnet,	IV ganciclovir,	IV then PO ganciclovir,	IV ganciclovir,	IV ganciclovir,	IV + IVit ganciclovir BE,
	IVit ganciclovir LE,	IV cidofovir	PO+ IVit ganciclovir LE	IV+ IVit ganciclovir LE,	PO ganciclovir+	IV foscarnet,	PO + IVit ganciclovir BE,
	IV cidofovir,			IVit foscarnet LE,	ganciclovir implant RE	IVit ganciclovir RE,	IVit foscarnet BE,
	PO ganciclovir			ganciclovir implant LE		IV cidofovir	IVit ganciclovir LE
Protease inhibitor	saquinavir, indinavir	indinavir	indinavir	indinavir	indinavir	indinavir	indinavir
start date	Mar 96	Oct 96	Nov 96	Aug 96	Apr 96	Apr 96	Sep 97
CD4 count
lowest	4	3	13	4	6	10	11
at onset vitritis	111	97	77	132	126	40	74
rise at onset vitritis	107	94	64	128	120	30	63
IRV
anterior chamber
cells	BE+	RE++, LE+	BE +	RE 0, LE+	RE+, LE 0	BE 0	BE ++
KPs	BE	BE	BE	0	BE	BE	BE
vitritis
onset	Jun 96	Mar 97	Dec 96	Jan 97	Jun 96	Jun 97	Dec 97
interval from starting PI	3 months	5 months	1 month	5 months	2 months	2 months	3 months
laterality and severity	BE ++	BE	LE +	RE silicone oil, LE ++	RE ++, LE +	BE ++	BE ++
macular changes	BE CMO	RE CMO	nil	nil	nil	nil	LE CMO
orbital floor steroid injections × number	methylpred ×1 BE triamcinolone ×1 BE	methylpred RE ×3	methylpred LE ×1	methylpred LE ×2	methylpred RE ×2	methylpred RE ××1 methylpred LE ×3	triamcinolone LE ×1
Snellen acuity
before IRV	BE 6/5	RE 6/6	LE 6/6	LE 6/ 5	BE 6/5	BE 6/5	LE 6/18
worst during IRV	RE 6/18, LE 6/9	RE 6/36	LE 6/9	LE 6/9	RE 6/24, L 6/6	RE 6/18, L6/12	LE 6/24
after treatment for IRV	BE 6/5	RE 6/18	LE 6/9	LE 6/6	BE 6/6	BE 6/9	LE 6/18
duration worst acuity	BE 3 wk	5 wk	indefinite	2 wk	6 wk	R 2 mo, L 1 wk	1 mo

LE=left eye, RE=right eye, BE=both eyes, IV=intravenous, PO=oral, IVit=intravitreal injection, M=male, mo=month, wk=week, methylpred=methylprednisolone acetate, CMV=cytomegalovirus, IRV=immune recovery vitritis, CMO=cystoid macular oedema, PI=protease inhibitor, CD4 count=CD4 T lymphocyte count (cells/μl).